ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis

Company Overview

ImmunoPrecise Antibodies Ltd. is a global biotechnology company specializing in the discovery, development and optimization of antibody-based therapeutics and research reagents. The company leverages a range of proprietary platforms—including mouse, rabbit, llama and human immune libraries, single B-cell screening, hybridoma technology and next-generation sequencing—to deliver custom monoclonal and polyclonal antibodies. Services extend from target validation through lead selection, with capabilities in epitope mapping, affinity maturation and immunoassay development.

Established in 2007 and headquartered in Victoria, British Columbia, ImmunoPrecise has expanded its footprint across North America, Europe and Asia. In addition to its Canadian operations, the company maintains research and development centers in Cambridge, UK, Seattle and Tianjin, China. This geographic diversity enables collaborations with pharmaceutical, biotechnology and academic clients seeking tailored antibody solutions for oncology, immunology, infectious disease and rare disorders.

ImmunoPrecise’s integrated service model supports programs at every stage of the discovery value chain. Early discovery workflows include antigen generation, in vivo immunization protocols and in vitro library screening, while later-stage services encompass cell line development, cell banking and process development for GMP manufacturing. The company’s continuous investment in platform enhancements—such as high-throughput sequencing and advanced bioinformatics—aims to accelerate timelines and improve candidate quality for challenging targets.

Under the leadership of Chief Executive Officer Dr. Daniel Kikly, ImmunoPrecise has pursued strategic partnerships and acquisitions to broaden its technology stack and market reach. The management team combines experience in monoclonal antibody research, diagnostics and biologics manufacturing, positioning the company to address evolving needs in drug discovery and translational research. As demand for bespoke antibody reagents grows, ImmunoPrecise seeks to capitalize on its established platforms and global network to support clients’ pipeline advancement and entry into clinical development.

Key Stats

• Today's Range: $1.54 to $1.79
• 50-Day Range: $0.44 to $1.76
• 52-Week Range: $0.27 to $1.79
• Volume: 2.60 million shs
• Average Volume: 2.55 million shs
• Market Capitalization: $80.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

ImmunoPrecise Antibodies Stock Analysis - MarketRank™

ImmunoPrecise Antibodies scored higher than 50% of companies evaluated by MarketBeat, and ranked 532nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

ImmunoPrecise Antibodies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ImmunoPrecise Antibodies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ImmunoPrecise Antibodies are expected to grow in the coming year, from ($0.27) to ($0.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ImmunoPrecise Antibodies is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImmunoPrecise Antibodies is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ImmunoPrecise Antibodies has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.50% of the float of ImmunoPrecise Antibodies has been sold short.

Short Interest Ratio / Days to Cover

ImmunoPrecise Antibodies has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ImmunoPrecise Antibodies has recently increased by 460.94%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImmunoPrecise Antibodies does not currently pay a dividend.

Dividend Growth

ImmunoPrecise Antibodies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.50% of the float of ImmunoPrecise Antibodies has been sold short.

Short Interest Ratio / Days to Cover

ImmunoPrecise Antibodies has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ImmunoPrecise Antibodies has recently increased by 460.94%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.68

News Sentiment

ImmunoPrecise Antibodies has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for ImmunoPrecise Antibodies this week, compared to 1 article on an average week.

Search Interest

12 people have searched for IPA on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added ImmunoPrecise Antibodies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ImmunoPrecise Antibodies insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.83% of the stock of ImmunoPrecise Antibodies is held by insiders.

Percentage Held by Institutions

Only 6.70% of the stock of ImmunoPrecise Antibodies is held by institutions.

IPA Stock Analysis - Frequently Asked Questions

How have IPA shares performed this year?

ImmunoPrecise Antibodies' stock was trading at $0.4117 at the beginning of 2025. Since then, IPA shares have increased by 327.5% and is now trading at $1.76.

How were ImmunoPrecise Antibodies' earnings last quarter?

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) announced its earnings results on Friday, March, 28th. The company reported ($0.06) EPS for the quarter, meeting analysts' consensus estimates of ($0.06). The company earned $4.23 million during the quarter, compared to the consensus estimate of $6.59 million. ImmunoPrecise Antibodies had a negative net margin of 190.76% and a negative trailing twelve-month return on equity of 88.87%.
Read the conference call transcript.

How do I buy shares of ImmunoPrecise Antibodies?

Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ImmunoPrecise Antibodies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoPrecise Antibodies investors own include NVIDIA (NVDA), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 3/28/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 4/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IPA
• CIK: 1715925
• Web: www.immunoprecise.com
• Phone: 250-483-0308
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ImmunoPrecise Antibodies: $4.00
• High Price Target: $5.00
• Low Price Target: $3.00
• Potential Upside/Downside: +127.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.13 million
• Net Margins: -190.76%
• Pretax Margin: -211.85%
• Return on Equity: -88.87%
• Return on Assets: -49.26%

Debt

• Debt-to-Equity Ratio: 0.45
• Current Ratio: 2.32
• Quick Ratio: 2.11

Sales & Book Value

• Annual Sales: $18.16 million
• Price / Sales: 4.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.93 per share
• Price / Book: 1.89

Miscellaneous

• Outstanding Shares: 45,760,000
• Free Float: 42,639,000
• Market Cap: $80.54 million
• Optionable: Not Optionable
• Beta: 0.44